Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Bevacizumab in EGFR-mutant Lung Cancers
NCT02803203Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2016
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02803203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02803203.